Abstract
Initial results of adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) appeared to offer promise for treating renal cell cancer (RCC). However, lower response rates were seen in subsequent trials, and the long-term results of this treatment method have not been fully reported. In this study, we examine long-term results of adoptive immunotherapy using LAK cells, IL-2, and cyclophosphamide (LAK/IL-2/CPM therapy). We administered 10 courses of therapy to 9 patients with advanced RCC. One patient had liver and para-aortic lymph node metastases; the others had only lung metastases. The clinical effects were initially evaluated 4 weeks after therapy and follow-up was continued for periods of 43 to 76 months. The 4-week evaluation revealed 3 complete responses (CR), 3 partial responses (PR), 1 minor response (MR), 1 patient with no change in disease status (NC), and 2 patients whose disease progressed (PD). One CR patient remained apparently free of disease for 43 months. After tumors recurred in the lung of another CR patient further disease progression was suppressed by IL-2 administration until the patient died from other causes at 46 months. The third CR patient showed tumor recurrence in...Continue Reading
References
Nov 1, 1992·Cancer Metastasis Reviews·K V Honn, D G Tang
Jun 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A ThompsonA Fefer
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R WeissM H Bar
Jul 1, 1991·Archives of Surgery·M J KoretzK M Sell
May 1, 1991·The Journal of Urology·J D Fleischmann, B Kim
Mar 1, 1991·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·E NakanoT Sonoda
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K A MargolinM Roper
Apr 1, 1988·Annals of Internal Medicine·R I FisherK A Margolin
Jan 1, 1988·Cancer Immunology, Immunotherapy : CII·M HosokawaH Kobayashi
Apr 9, 1987·The New England Journal of Medicine·S A RosenbergJ T Rubin
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham
May 1, 1995·Current Opinion in Oncology·P D Savage
Mar 16, 1995·International Journal of Cancer. Journal International Du Cancer·Y TomitaS Sato
May 3, 1996·International Journal of Cancer. Journal International Du Cancer·Y TomitaK G Wiman
Sep 27, 1996·International Journal of Cancer. Journal International Du Cancer·Y TomitaK Takahashi
Citations
Jan 17, 2002·Journal of Immunological Methods·Ahmad GharehbaghianBenjamin A Bradley
Apr 27, 2000·Critical Reviews in Oncology/hematology·A J Bremers, G Parmiani
Apr 3, 2014·Archives of Pharmacal Research·Ji Sung KimSang-Bae Han
Dec 3, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Abhishek TripathiLauren C Harshman
Mar 23, 2002·Cancer Treatment Reviews·G G GomezC A Kruse
Aug 1, 2016·Current Oncology Reports·Susanna A CurtisHarriet M Kluger
Jan 15, 2015·Cancer Treatment Reviews·F MassariG Tortora
Jul 7, 2017·Investigative and Clinical Urology·Yang Hyun ChoEu Chang Hwang
Sep 14, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Mayer Fishman, John Seigne
Aug 29, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Escudier